CompletedNCT00320671
Aripiprazole or risperidone for first-episode psychosis
About this title
Read the official source — NCT00320671Medication studyAges 15–40United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 15 years to 40 years.
- Listed locations
- Glen OaksSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 198
- Sponsor
- Northwell Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 15 Years to 40 Years
- Official registry ID
- NCT00320671
- Official title
Show the full official title
Preventing Morbidity in First Episode Schizophrenia, Part II
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glen Oaks
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Northwell Health.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Risperidone.
Who was this study for?
Listed age limits: 15 years to 40 years.
